_id
691055ecccc777a4e85d55f4
Ticker
CSPHF
Name
CStone Pharmaceuticals
Exchange
PINK
Address
C1 Building, Suzhou, China, 215123
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cstonepharma.com
Description
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma. The company's products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Last Close
0.893
Volume
-
Current Price
0.689
Change
0
Last Updated
2026-01-02T12:05:37.049Z
Image
-
Ipo Date
-
Market Cap
1343848576
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
24725500
Cost Of Revenue
71120500
Gross Profit
-46395000
Operating Expenses
92183000
Operating Income
-138578000
Interest Expense
2910500
Pretax Income
-135091500
Net Income
-135091500
Eps
-0.10279848630928692
Dividends Per Share
-
Shares Outstanding
1461101875
Income Tax Expense
-
EBITDA
-133102500
Operating Margin
-560.4659157549899
Total Other Income Expense Net
3486500
Cash
457766000
Short Term Investments
195000000
Receivables
99872000
Inventories
148851000
Total Current Assets
901489000
Property Plant Equipment
109985000
Total Assets
1191905000
Payables
212085000
Short Term Debt
219947000
Long Term Debt
169200000
Total Liabilities
876861000
Equity
315044000
Bs_currency_symbol
CNY
Depreciation
3324000
Change In Working Capital
-
Cash From Operations
-
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-
Cf_currency_symbol
-
PE
-
PB
2.8740168706593363
ROE
-42.88020086083213
ROA
-11.334082833782894
FCF
-
Fcf Percent
-
Piotroski FScore
0
Health Score
28
Deep Value Investing Score
2.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1
Growth Investing Score
1
Momentum Investing Score
5
Net Net Investing Score
1.5
Quality Investing Score
1
Value Investing Score
2
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
24725500
Quarters > 0 > income Statement > cost Of Revenue
71120500
Quarters > 0 > income Statement > gross Profit
-46395000
Quarters > 0 > income Statement > operating Expenses
92183000
Quarters > 0 > income Statement > operating Income
-138578000
Quarters > 0 > income Statement > interest Expense
2910500
Quarters > 0 > income Statement > pretax Income
-135091500
Quarters > 0 > income Statement > net Income
-135091500
Quarters > 0 > income Statement > eps
-0.10279848630928692
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1314139000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-133102500
Quarters > 0 > income Statement > operating Margin
-560.4659157549899
Quarters > 0 > income Statement > total Other Income Expense Net
3486500
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
457766000
Quarters > 0 > balance Sheet > short Term Investments
195000000
Quarters > 0 > balance Sheet > receivables
99872000
Quarters > 0 > balance Sheet > inventories
148851000
Quarters > 0 > balance Sheet > total Current Assets
901489000
Quarters > 0 > balance Sheet > property Plant Equipment
109985000
Quarters > 0 > balance Sheet > total Assets
1191905000
Quarters > 0 > balance Sheet > payables
212085000
Quarters > 0 > balance Sheet > short Term Debt
219947000
Quarters > 0 > balance Sheet > long Term Debt
169200000
Quarters > 0 > balance Sheet > total Liabilities
876861000
Quarters > 0 > balance Sheet > equity
315044000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
-270183000
Quarters > 0 > cash Flow > depreciation
3324000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.10279848630928692
Quarters > 0 > ratios > PB
2.8740168706593363
Quarters > 0 > ratios > ROE
-42.88020086083213
Quarters > 0 > ratios > ROA
-11.334082833782894
Quarters > 0 > ratios > FCF
-
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
28
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
24725500
Quarters > 1 > income Statement > cost Of Revenue
71120500
Quarters > 1 > income Statement > gross Profit
-46395000
Quarters > 1 > income Statement > operating Expenses
92183000
Quarters > 1 > income Statement > operating Income
-138578000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-135091500
Quarters > 1 > income Statement > net Income
-135091500
Quarters > 1 > income Statement > eps
-0.10279848630928692
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
1314139000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-133102499
Quarters > 1 > income Statement > operating Margin
-560.4659157549899
Quarters > 1 > income Statement > total Other Income Expense Net
3486500
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
457766000
Quarters > 1 > balance Sheet > short Term Investments
232336000
Quarters > 1 > balance Sheet > receivables
62536000
Quarters > 1 > balance Sheet > inventories
148851000
Quarters > 1 > balance Sheet > total Current Assets
901489000
Quarters > 1 > balance Sheet > property Plant Equipment
109985000
Quarters > 1 > balance Sheet > total Assets
1191905000
Quarters > 1 > balance Sheet > payables
212085000
Quarters > 1 > balance Sheet > short Term Debt
219947000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
876861000
Quarters > 1 > balance Sheet > equity
315044000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-135091500
Quarters > 1 > cash Flow > depreciation
3324000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.10279848630928692
Quarters > 1 > ratios > PB
2.8740168706593363
Quarters > 1 > ratios > ROE
-42.88020086083213
Quarters > 1 > ratios > ROA
-11.334082833782894
Quarters > 1 > ratios > FCF
-
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
28
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
153040000
Quarters > 2 > income Statement > cost Of Revenue
84915000
Quarters > 2 > income Statement > gross Profit
68125000
Quarters > 2 > income Statement > operating Expenses
170548000
Quarters > 2 > income Statement > operating Income
-102423000
Quarters > 2 > income Statement > interest Expense
1590000
Quarters > 2 > income Statement > pretax Income
-106906000
Quarters > 2 > income Statement > net Income
-106906000
Quarters > 2 > income Statement > eps
-0.08372412842513494
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
1276884000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-85282000
Quarters > 2 > income Statement > operating Margin
-66.92564035546262
Quarters > 2 > income Statement > total Other Income Expense Net
-4483000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
387937000
Quarters > 2 > balance Sheet > short Term Investments
285000000
Quarters > 2 > balance Sheet > receivables
130875000
Quarters > 2 > balance Sheet > inventories
286096000
Quarters > 2 > balance Sheet > total Current Assets
1089908000
Quarters > 2 > balance Sheet > property Plant Equipment
130543000
Quarters > 2 > balance Sheet > total Assets
1393466000
Quarters > 2 > balance Sheet > payables
338029000
Quarters > 2 > balance Sheet > short Term Debt
93216000
Quarters > 2 > balance Sheet > long Term Debt
257400000
Quarters > 2 > balance Sheet > total Liabilities
1029595000
Quarters > 2 > balance Sheet > equity
363871000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
-106906000
Quarters > 2 > cash Flow > depreciation
25798000
Quarters > 2 > cash Flow > change In Working Capital
-48201000
Quarters > 2 > cash Flow > cash From Operations
-156049000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-149950000
Quarters > 2 > cash Flow > cash From Financing
22577000
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.08372412842513494
Quarters > 2 > ratios > PB
2.417815863314196
Quarters > 2 > ratios > ROE
-29.380192430834008
Quarters > 2 > ratios > ROA
-7.671948938833097
Quarters > 2 > ratios > FCF
-156049000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-1.0196615263983273
Quarters > 2 > health Score
20
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
76520000
Quarters > 3 > income Statement > cost Of Revenue
42457500
Quarters > 3 > income Statement > gross Profit
34062500
Quarters > 3 > income Statement > operating Expenses
85274000
Quarters > 3 > income Statement > operating Income
-51211500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-53453000
Quarters > 3 > income Statement > net Income
-53453000
Quarters > 3 > income Statement > eps
-0.04186206421256747
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
1276884000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-42641000
Quarters > 3 > income Statement > operating Margin
-66.92564035546262
Quarters > 3 > income Statement > total Other Income Expense Net
-2241500
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
387937000
Quarters > 3 > balance Sheet > short Term Investments
331946000
Quarters > 3 > balance Sheet > receivables
83929000
Quarters > 3 > balance Sheet > inventories
286096000
Quarters > 3 > balance Sheet > total Current Assets
1089908000
Quarters > 3 > balance Sheet > property Plant Equipment
130543000
Quarters > 3 > balance Sheet > total Assets
1393466000
Quarters > 3 > balance Sheet > payables
338029000
Quarters > 3 > balance Sheet > short Term Debt
93215999
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
1029595000
Quarters > 3 > balance Sheet > equity
363871000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-53453000
Quarters > 3 > cash Flow > depreciation
12899000
Quarters > 3 > cash Flow > change In Working Capital
-24100500
Quarters > 3 > cash Flow > cash From Operations
-78024500
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-74975000
Quarters > 3 > cash Flow > cash From Financing
11288500
Quarters > 3 > cash Flow > net Change In Cash
-
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.04186206421256747
Quarters > 3 > ratios > PB
2.417815863314196
Quarters > 3 > ratios > ROE
-14.690096215417004
Quarters > 3 > ratios > ROA
-3.8359744694165485
Quarters > 3 > ratios > FCF
-78024500
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-1.0196615263983273
Quarters > 3 > health Score
20
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
407205000
Annuals > 0 > income Statement > cost Of Revenue
167051000
Annuals > 0 > income Statement > gross Profit
240154000
Annuals > 0 > income Statement > operating Expenses
331846000
Annuals > 0 > income Statement > operating Income
-91692000
Annuals > 0 > income Statement > interest Expense
15167000
Annuals > 0 > income Statement > pretax Income
-91207000
Annuals > 0 > income Statement > net Income
-91207000
Annuals > 0 > income Statement > eps
-0.07146775030206912
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
1276198000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-26235000
Annuals > 0 > income Statement > operating Margin
-22.517405238147862
Annuals > 0 > income Statement > total Other Income Expense Net
485000
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
387937000
Annuals > 0 > balance Sheet > short Term Investments
285000000
Annuals > 0 > balance Sheet > receivables
130875000
Annuals > 0 > balance Sheet > inventories
286096000
Annuals > 0 > balance Sheet > total Current Assets
1089908000
Annuals > 0 > balance Sheet > property Plant Equipment
130543000
Annuals > 0 > balance Sheet > total Assets
1393466000
Annuals > 0 > balance Sheet > payables
338029000
Annuals > 0 > balance Sheet > short Term Debt
93216000
Annuals > 0 > balance Sheet > long Term Debt
257400000
Annuals > 0 > balance Sheet > total Liabilities
1029595000
Annuals > 0 > balance Sheet > equity
363871000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-91207000
Annuals > 0 > cash Flow > depreciation
49805000
Annuals > 0 > cash Flow > change In Working Capital
-302800000
Annuals > 0 > cash Flow > cash From Operations
-343181000
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-247679000
Annuals > 0 > cash Flow > cash From Financing
-12896000
Annuals > 0 > cash Flow > net Change In Cash
-608734000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-0.07146775030206912
Annuals > 0 > ratios > PB
3.132002314006887
Annuals > 0 > ratios > ROE
-25.065751323958217
Annuals > 0 > ratios > ROA
-6.5453337218130905
Annuals > 0 > ratios > FCF
-343181000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.8427720681229356
Annuals > 0 > health Score
15
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
463842000
Annuals > 1 > income Statement > cost Of Revenue
159547000
Annuals > 1 > income Statement > gross Profit
304295000
Annuals > 1 > income Statement > operating Expenses
884140000
Annuals > 1 > income Statement > operating Income
-579845000
Annuals > 1 > income Statement > interest Expense
11819000
Annuals > 1 > income Statement > pretax Income
-367234000
Annuals > 1 > income Statement > net Income
-367234000
Annuals > 1 > income Statement > eps
-0.2907464572514811
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
1263073000
Annuals > 1 > income Statement > income Tax Expense
58022105
Annuals > 1 > income Statement > EBITDA
-297225000
Annuals > 1 > income Statement > operating Margin
-125.00916260278285
Annuals > 1 > income Statement > total Other Income Expense Net
212611000
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
996671000
Annuals > 1 > balance Sheet > short Term Investments
51850000
Annuals > 1 > balance Sheet > receivables
172438000
Annuals > 1 > balance Sheet > inventories
108828000
Annuals > 1 > balance Sheet > total Current Assets
1329787000
Annuals > 1 > balance Sheet > property Plant Equipment
153368000
Annuals > 1 > balance Sheet > total Assets
1661999000
Annuals > 1 > balance Sheet > payables
246377000
Annuals > 1 > balance Sheet > short Term Debt
139313000
Annuals > 1 > balance Sheet > long Term Debt
213000000
Annuals > 1 > balance Sheet > total Liabilities
1205169000
Annuals > 1 > balance Sheet > equity
456830000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-367234000
Annuals > 1 > cash Flow > depreciation
58190000
Annuals > 1 > cash Flow > change In Working Capital
-139666000
Annuals > 1 > cash Flow > cash From Operations
-588843000
Annuals > 1 > cash Flow > capital Expenditures
65047000
Annuals > 1 > cash Flow > cash From Investing
619605000
Annuals > 1 > cash Flow > cash From Financing
388355000
Annuals > 1 > cash Flow > net Change In Cash
437987000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-0.2907464572514811
Annuals > 1 > ratios > PB
2.4690239016702056
Annuals > 1 > ratios > ROE
-80.38745266291617
Annuals > 1 > ratios > ROA
-22.095921838701468
Annuals > 1 > ratios > FCF
-653890000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-1.409725725570345
Annuals > 1 > health Score
21
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
481363000
Annuals > 2 > income Statement > cost Of Revenue
202985000
Annuals > 2 > income Statement > gross Profit
278378000
Annuals > 2 > income Statement > operating Expenses
1190525000
Annuals > 2 > income Statement > operating Income
-912147000
Annuals > 2 > income Statement > interest Expense
8477000
Annuals > 2 > income Statement > pretax Income
-902678000
Annuals > 2 > income Statement > net Income
-902678000
Annuals > 2 > income Statement > eps
-0.7696521005866961
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
1172839000
Annuals > 2 > income Statement > income Tax Expense
61929000
Annuals > 2 > income Statement > EBITDA
-849661000
Annuals > 2 > income Statement > operating Margin
-189.49254512706625
Annuals > 2 > income Statement > total Other Income Expense Net
9469000
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
558684000
Annuals > 2 > balance Sheet > short Term Investments
483407000
Annuals > 2 > balance Sheet > receivables
77133000
Annuals > 2 > balance Sheet > inventories
22188000
Annuals > 2 > balance Sheet > total Current Assets
1246917000
Annuals > 2 > balance Sheet > property Plant Equipment
206566000
Annuals > 2 > balance Sheet > total Assets
1638427000
Annuals > 2 > balance Sheet > payables
290414000
Annuals > 2 > balance Sheet > short Term Debt
44918000
Annuals > 2 > balance Sheet > long Term Debt
218986000
Annuals > 2 > balance Sheet > total Liabilities
1189101000
Annuals > 2 > balance Sheet > equity
449326000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-902678000
Annuals > 2 > cash Flow > depreciation
44540000
Annuals > 2 > cash Flow > change In Working Capital
72647000
Annuals > 2 > cash Flow > cash From Operations
-612469000
Annuals > 2 > cash Flow > capital Expenditures
101821000
Annuals > 2 > cash Flow > cash From Investing
365119000
Annuals > 2 > cash Flow > cash From Financing
28467000
Annuals > 2 > cash Flow > net Change In Cash
-184040000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-0.7696521005866961
Annuals > 2 > ratios > PB
2.330925045512612
Annuals > 2 > ratios > ROE
-200.8960086885691
Annuals > 2 > ratios > ROA
-55.0941848492487
Annuals > 2 > ratios > FCF
-714290000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-1.4838905358326253
Annuals > 2 > health Score
20
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
243718000
Annuals > 3 > income Statement > cost Of Revenue
106832000
Annuals > 3 > income Statement > gross Profit
136886000
Annuals > 3 > income Statement > operating Expenses
1966329000
Annuals > 3 > income Statement > operating Income
-1829443000
Annuals > 3 > income Statement > interest Expense
2242000
Annuals > 3 > income Statement > pretax Income
-1920100000
Annuals > 3 > income Statement > net Income
-1920100000
Annuals > 3 > income Statement > eps
-1.6478588819688142
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
1165209000
Annuals > 3 > income Statement > income Tax Expense
67347000
Annuals > 3 > income Statement > EBITDA
-1895197000
Annuals > 3 > income Statement > operating Margin
-750.6392634109914
Annuals > 3 > income Statement > total Other Income Expense Net
-90657000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
742724000
Annuals > 3 > balance Sheet > short Term Investments
983615000
Annuals > 3 > balance Sheet > receivables
117598000
Annuals > 3 > balance Sheet > inventories
61363000
Annuals > 3 > balance Sheet > total Current Assets
1957645000
Annuals > 3 > balance Sheet > property Plant Equipment
187923000
Annuals > 3 > balance Sheet > total Assets
2271453000
Annuals > 3 > balance Sheet > payables
414293000
Annuals > 3 > balance Sheet > short Term Debt
43948000
Annuals > 3 > balance Sheet > long Term Debt
115811000
Annuals > 3 > balance Sheet > total Liabilities
1064445000
Annuals > 3 > balance Sheet > equity
1207008000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-1920100000
Annuals > 3 > cash Flow > depreciation
22661000
Annuals > 3 > cash Flow > change In Working Capital
64520000
Annuals > 3 > cash Flow > cash From Operations
-1484024000
Annuals > 3 > cash Flow > capital Expenditures
149136000
Annuals > 3 > cash Flow > cash From Investing
-826552000
Annuals > 3 > cash Flow > cash From Financing
92304000
Annuals > 3 > cash Flow > net Change In Cash
-2281824000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-1.6478588819688142
Annuals > 3 > ratios > PB
0.8620751784578063
Annuals > 3 > ratios > ROE
-159.07931016198734
Annuals > 3 > ratios > ROA
-84.5317952869815
Annuals > 3 > ratios > FCF
-1633160000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-6.701023313829918
Annuals > 3 > health Score
29
Valuation > metrics > PE
-0.10279848630928692
Valuation > metrics > PB
2.8740168706593363
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-42.88020086083213
Profitability > metrics > ROA
-14.985374197577563
Profitability > metrics > Net Margin
-5.463650886736366
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
2.783296936300961
Risk > metrics > Interest Coverage
-47.61312489263013
Risk > final Score
-172
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.086625527738686
Liquidity > metrics > Quick Ratio
1.7420885489963707
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-261
Prev Risks > 1
-240
Prev Risks > 2
-1
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:40:01.168Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
CNY
Earnings History > 1 > eps Actual
-0.0519
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.0519
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-25
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
BeforeMarket
Earnings History > 2 > currency
CNY
Earnings History > 2 > eps Actual
-0.0511
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.0511
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-09-30
Earnings History > 3 > report Date
2020-12-31
Earnings History > 3 > date
2020-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
CNY
Earnings History > 3 > eps Actual
-0.0392
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.0392
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-06-30
Earnings History > 4 > report Date
2020-08-18
Earnings History > 4 > date
2020-06-30
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
CNY
Earnings History > 4 > eps Actual
-0.0377
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.0377
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2020-03-31
Earnings History > 5 > report Date
2020-06-30
Earnings History > 5 > date
2020-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
CNY
Earnings History > 5 > eps Actual
-0.0469
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.0469
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-12-31
Earnings History > 6 > report Date
2020-03-26
Earnings History > 6 > date
2019-12-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
CNY
Earnings History > 6 > eps Actual
-0.0468
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-0.0468
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-09-30
Earnings History > 7 > report Date
2019-12-31
Earnings History > 7 > date
2019-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
CNY
Earnings History > 7 > eps Actual
-0.0777
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-0.0777
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2019-06-30
Earnings History > 8 > report Date
2019-08-14
Earnings History > 8 > date
2019-06-30
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
CNY
Earnings History > 8 > eps Actual
-0.0757
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-0.0757
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2019-03-31
Earnings History > 9 > report Date
2019-06-30
Earnings History > 9 > date
2019-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
CNY
Earnings History > 9 > eps Actual
-0.0981
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-0.0981
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2018-12-31
Earnings History > 10 > report Date
2019-03-22
Earnings History > 10 > date
2018-12-31
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
CNY
Earnings History > 10 > eps Actual
-0.1004
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.1004
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2018-09-30
Earnings History > 11 > report Date
2018-12-31
Earnings History > 11 > date
2018-09-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
CNY
Earnings History > 11 > eps Actual
-0.1243
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-0.1243
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2018-03-31
Earnings History > 12 > report Date
2018-06-30
Earnings History > 12 > date
2018-03-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
CNY
Earnings History > 12 > eps Actual
-0.1031
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
-0.1031
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2017-12-31
Earnings History > 13 > report Date
2018-03-31
Earnings History > 13 > date
2017-12-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
CNY
Earnings History > 13 > eps Actual
-0.1088
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
-0.1088
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2017-09-30
Earnings History > 14 > report Date
2017-12-31
Earnings History > 14 > date
2017-09-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
CNY
Earnings History > 14 > eps Actual
-0.0208
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
-0.0208
Earnings History > 14 > surprise Percent
-
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma. The company's products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of CStone Pharmaceuticals
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2021-03-31
EPS Actual
-0.0519
EPS Estimate
0
EPS Difference
-0.0519
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.